Johnson & Johnson stock (US4781601046): Shares up 2.8% on analyst upgrade

Johnson & Johnson shares climbed 2.8% to $230.80 on May 13, 2026, following an upgrade to outperform by Johnson Rice. Recent Q1 earnings beat estimates with $24.06B revenue, and dividend raised to $1.34.

Johnson & Johnson shares rose 2.8% on May 13, 2026, reaching a high of $230.80 after Johnson Rice upgraded the stock from hold to outperform, according to MarketBeat as of May 13, 2026. The stock had closed at $224.26 the prior day. This move aligns with bullish sentiment from other analysts like Guggenheim and Goldman Sachs, amid strong Q1 results reported on April 14, 2026, with revenue of $24.06 billion up 9.9% year-over-year and EPS of $2.70 beating estimates, per MarketBeat as of May 14, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare / Pharmaceuticals
• Headquarters/country: United States
• Core markets: Global, with strong US presence
• Key revenue drivers: Innovative Medicine, MedTech
• Home exchange/listing venue: NYSE (JNJ)
• Trading currency: USD

Johnson & Johnson: core business model

Johnson & Johnson operates as a global healthcare leader, divided into two main segments: Innovative Medicine and MedTech. The Innovative Medicine unit focuses on pharmaceuticals, including immunology, oncology, neuroscience, cardiovascular, and infectious diseases. MedTech covers products like orthopaedics, vision care, and surgical equipment. This diversified model serves patients, consumers, and professionals worldwide, with significant exposure to the US market through its NYSE listing.

The company's strategy emphasizes innovation, with a robust pipeline including TREMFYA advancements and new launches like the Shockwave C2 Aero coronary IVL catheter, supporting investor interest in its growth prospects.

Main revenue and product drivers for Johnson & Johnson

Revenue growth is propelled by key products in immunology and oncology, alongside MedTech innovations. In Q1 2026, reported April 14, 2026, operational revenue grew 9.9% to $24.06 billion, driven by strong performances in these areas. The firm guided FY 2026 adjusted EPS at $11.45-$11.65, reflecting confidence in sustained momentum.

Dividend reliability remains a cornerstone, with the quarterly payout increased to $1.34 per share, payable June 9, 2026, to shareholders of record May 26, 2026, yielding about 2.3% annualized. This marks a rise from $1.30 previously, underscoring financial strength with a payout ratio of 60.12% as of the latest report.

Industry trends and competitive position

Johnson & Johnson holds a premier position in healthcare, benefiting from aging populations and demand for advanced therapies in the US and globally. Its market cap stood at approximately $554.69 billion recently, with a P/E ratio of 26.64 and low beta of 0.27, indicating stability attractive to US investors seeking defensive plays amid market volatility.

Why Johnson & Johnson matters for US investors

As a NYSE-listed blue-chip with deep US roots, Johnson & Johnson offers exposure to resilient healthcare demand. Its products address critical needs in the world's largest pharma market, providing a hedge against economic cycles while tapping into innovation-driven growth relevant to American portfolios.

Conclusion

Johnson & Johnson continues to demonstrate resilience with recent share price gains on analyst upgrades, solid Q1 earnings, and a dividend hike. Pipeline momentum in oncology and immunology bolsters its outlook, while its stable metrics appeal to long-term holders. US investors track these developments closely given the company's market leadership and NYSE presence.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.